medigraphic.com
Órgano Oficial de la Sociedad Mexicana de Angiología y Cirugía Vascular

2014, Number 2

<< Back Next >>

Rev Mex Angiol 2014; 42 (2)

Percepción de calidad de vida asociada al uso de pentoxifilina en pacientes con insuficiencia venosa crónica en primer nivel de atención del IMSS

Barranco-Guida E, Bravo-Arriola E, Díaz-Hernández A, Payán-Vivas E

Language: Spanish
References: 18
Page: 76-85
PDF size: 190.14 Kb.


ABSTRACT

Background. The chronic venous insufficiency (CVI) has a worldwide prevalence of 10-15%. From Clinical Practice Guidelines (CPG) the pentoxifylline that is used is justified only in an advanced stage (CEAP 6). However, prescription begins in early stages, justifying an improvement in the quality of patients’s life, reducing their symptoms, with no scientific evidence to support.
Objective. To determine the difference about the perception of quality life using the pentoxifylline for patients with (CVI) during primary care.
Material and methods. Cross-sectional study included patients with CVI (n = 110), in 2013 in the Unidad de Medicina Familiar 11 of the Instituto Mexicano del Seguro Social. Sample size for a proportion, probability sampling, simple random allocation; using the instrument CIVIQ-20 for quality of life (alpha-Cronbach 0.820, p ‹ 0.001) and CEAP classification. It was performed descriptive and inferential statistics (t Student) and numerical multiple regression in SPSS20.
Results. The attachment to GPC was 55.45%, patients used pentoxifylline showed less life quality (X 46.36 vs. 29.57, t-4.610, p 0.000) and an OR of 0.20 (IC95% 0.77-0.54), the type of numerical multiple regression (p 0.000) showed that variables with the highest impact for explanation about the life quality model were: psychologist function and pain (β 0.445 and β, 0.249 p 0.000).
Conclusions. The use of pentoxifylline is related to a bad quality of life in patients with CVI, discovering that C2 and C3 with highest prevalence, besides to show a bad attachment to CPG.


REFERENCES

  1. Kurz X, Kahn SR, Abenhaim L, Clement D, Norgren L, Bacaglini U, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the veines task force. Int Angiol 1999; 18: 83-102.

  2. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F; VCP coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the vein consult program. Int Angiol 2012; 31: 105-15.

  3. Gesto-Castromil R, Grupo Detect-IVC, García JJ. Encuesta epidemiológica realizada en España sobre la prevalencia asistencial de la insuficiencia venosa crónica en atención primaria. Estudio Detect-IVC. Angiología 2001; 53: 249-60.

  4. Información epidemiológica de morbilidad 2002. Secretaría de Salud. Available from: http:// www.epidemiologia.salud.gob.mx/anuario/html/ anuarios.html

  5. Pizano Ramírez, Norman Diego. Anatomía normal de las venas de los miembros inferiores y de la pelvis. Flebología práctica. Guías para el diagnóstico y el manejo de las enfermedades de las venas. 1a Ed. Cartopel S.A. Impresores, Cali; 2003.

  6. Eklöf B, Rutherford Rb, Bergan Jj, Carpentier Ph, Gloviczki P, Kistner Rl, Meissner Mh, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40: 1248-52.

  7. Kakkos SK, Rivers MA, Matsagas MI, et al. Validation of the new venous severity scoring system in varicose vein surgery. J Vasc Surg 2003; 38: 224-8.

  8. Jones R, Carek P. Management of varicose veins. Am Fam Physician 2008; 78: 1289-94.

  9. Martínez MJ, Bonfill X, Moreno RM, Vargas E, Capellá D. Flebotónicos para la insuficiencia venosa (revisión Cochrane traducida). En: Biblioteca Cochrane Plus, 2008 número 2. Oxford: update software w ltd. Disponible en: http://www.update-software.com (Traducida de the Cochrane Library, 2008 issue 2. Chichester, uk: john wiley & sons, ltd.).

  10. Jull A, Arroll B, Parag V, Waters J. Pentoxifilina para el tratamiento de la úlcera venosa de pierna (revisión Cochrane traducida). En: la biblioteca Cochrane plus 2008 número 2 Oxford: update software ltd. Disponible en: http://www.update-software.com

  11. Nikolovska S, Pavlova L, Petrova N, Gocev G, Ivanovski M. Pentoxifylline–efficient in the treatment of venous ulcers in the absence of compression? Acta Dermatovenerol Croat 2002; 10: 9-13.

  12. Korlaar I, Vossen C, Rosendaal F, Cameron L, Bovill E, Kaptein A. Quality of life in venous disease. Trombosis and haemostasis 2003; 90: 27-35.

  13. Salinas P, Farias A, González X, Rodríguez C. Calidad de vida relacionada en salud: concepto y evaluación en pacientes con ventilación mecánica no invasiva. Disponible en: http://www.neumologia-pediatrica.cl

  14. Velarde E, Ávila C. Consideraciones metodológicas para evaluar la calidad de vida. Sal Pub Mex 2002; 44: 448-63.

  15. Franks Pj, Moffatt Cj. Health related quality of life in patients with venous ulceration: use of the Nottingham health profile. Quality of life research 2001; 10: 693-700.

  16. Rosas Flores MA, Serrano Lozano A, et al. Calidad de vida en pacientes con insuficiencia venosa crónica. Cirujano general 2006; 28: 153-15.

  17. Straus JL Von Ammon, Cavanaught S. Placebo effects. Issues for clinical practice in psychiatry and medicine. Psychosomatics 1996; 37: 315-26.

  18. Declaración de Helsinki de la Asociación Médica Mundial, ARBOR CLXXXIV Núm. 730, 2008.




2020     |     www.medigraphic.com